Overview
correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)
Description
This is a prospective study that will carried out in Department of cardiology, Faculty of Medicine, Fayoum University during the period from 1 April 2024 to 1 Juley 2024. The study includes 90 Outpatients Clinic patients who met the inclusion criteria. Patients will provide written informed consent before involving in this study.
- we will split the 90 patients into three groups:
- 30 patients will take statin.
- 30 patients will take SGLT2i.
- 30 patients will take both of statin and SGLT2i.
- By collecting their blood samples and calculate the serum level of statin by using HPLC and calculate plasma level of SGLT2i by using HPLC as baseline first then after three months to predict the effect of each drug to another one, we will follow their cholesterol, triglyceride, low density lipo-protein and high density lipo-protein and we will also inspect their adverse effects.
Eligibility
Inclusion Criteria:
- we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease,
- They assessed the use of statin with SGLT2i.
Exclusion Criteria:
- We exclude patients with
- liver dysfunction.
- renal dysfunction.
- fungal infection.
- coagulation disorder.
- Pts using drugs that interact with SGLT2i.
- patients that will refuse to be enrolled in the Study or refuse to write informed consent.